PharmaMedic /
  • Home
  • Our Services
    • Start-Up
    • Product Launch
    • Product Development
  • Join Us
  • About Us
    • Our Vision
    • Dr Malcolm Barratt-Johnson
  • Resources
  • News
  • Contact Us
PharmaMedic
  • Home
  • Our Services
    • Start-Up
    • Product Launch
    • Product Development
  • Join Us
  • About Us
    • Our Vision
    • Dr Malcolm Barratt-Johnson
  • Resources
  • News
  • Contact Us

General

News Category

Posts navigation

1 2 … 14 Next
UK’s MRC invests in research into hard-to-treat cancers

UK’s MRC invests in research into hard-to-treat cancers

UK Research and Innovation’s (UKRI) Medical Research Council (MRC) is investing £2 million to support research into cancers with poor survival rates. These include studies into cancers of the brain, lung and oesophagus.

18 Sep 2023
Read More
Government funds to grow UK life sciences workforce and upgrade science facility

Government funds to grow UK life sciences workforce and upgrade science facility

As part of its £650m ‘Life Sci for Growth’ scheme to boost the life sciences sector and the wider economy, the government will establish a Medicines Manufacturing Skills Centre of Excellence with a dedicated £5.5m fund.

13 Sep 2023
Read More
UK rejoins Horizon Europe

UK rejoins Horizon Europe

Britain’s life science community is celebrating the country’s return to the EU Horizon Europe research programme, which was announced on 7 September 2023.

11 Sep 2023
Read More
Public and HCP trust in UK pharma industry maintained

Public and HCP trust in UK pharma industry maintained

The third annual Pharma Reputation Index, commissioned by the Association of the British Pharmaceutical Industry (ABPI), has found that the public looks favourably on the industry and continues to recognise its commitment to developing new medicines.

7 Sep 2023
Read More
MHRA consults on ending EC Decision Reliance Procedure

MHRA consults on ending EC Decision Reliance Procedure

The Medicines and Healthcare products Regulatory Agency (MHRA) is inviting feedback on plans to end use of the European Commission Decision Reliance Procedure (ECDRP) to bring medicines to market.

4 Sep 2023
Read More
Still no UK-EU agreement on Horizon Europe

Still no UK-EU agreement on Horizon Europe

Roadblocks from the EU, and the UK government’s determination to get a ‘fair settlement’ on associate membership, are harming international collaborative research programmes and, ultimately, patients’ access to innovative treatments and devices.

16 Aug 2023
Read More
Clarification on continuation of CE marking in UK

Clarification on continuation of CE marking in UK

The UK’s Department for Business and Trade (DBT) has announced an indefinite extension to the use of CE marking for businesses in the UK, beyond the 2024 deadline. The aim is to cut business costs and products’ time to market. The government intends to implement major reforms to the current regulatory framework for medical devices, with core parts set to apply from 1 July 2025.

7 Aug 2023
Read More
MHRA publishes annual report for 2022-2023

MHRA publishes annual report for 2022-2023

The UK Medicines and Healthcare products Regulatory Agency’s (MHRA) annual report and accounts for 2022-2023 was printed on 19 July 2023. The report outlines achievements during the year, such as its evolution into a ‘One Agency’ organisation, uniting its regulatory, research and standards and clinical data service.

31 Jul 2023
Read More
UK government consults on draft legislation on merged R&D tax relief

UK government consults on draft legislation on merged R&D tax relief

Draft legislation has been published by the UK government on a proposed merged R&D tax relief scheme. If implemented, the reform would affect companies claiming R&D tax relief under either the Research and Development Expenditure Credit (RDEC) or the small or medium enterprises (SME) R&D relief.

25 Jul 2023
Read More
Pharma organisations tussle over VPAS negotiations

Pharma organisations tussle over VPAS negotiations

A High Court judgment on a judicial review brought by the British Generic Manufacturers Association (BGMA) has dismissed the organisation’s claim that it was unfairly excluded from talks on the next Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).

20 Jul 2023
Read More

Posts navigation

1 2 … 14 Next

GeneralCategories

  • No categories

GeneralTags

#ABPI #BIA #cancer #ClinicalTrials #drugapprovals #drugpricing #drugregulation #EC #EFPIA #EMA #EU #FDA #HorizonEurope #HTA #innovation #lifesciences #marketaccess #MDR #medicalaffairs #medicaldevice #medicinesaccess #medtech #mentalhealth #mhra #NHS #NICE #patients #pharmaregulation #pre-eclampsia #R&D #rarediseases #regulation #regulatory #research #startups #UKgovernment #ukpharma #ukregulation #VPAS AI Biotech COVID-19 Healthcare medicaldevices Pharma
PharmaMedic
  • Home
  • Join Us
  • Our Vision
  • Dr Malcolm Barratt-Johnson
  • Resources
  • News
  • Contact Us
Our Services
  • Start-Up
  • Product Launch
  • Product Development
Legal
  • Privacy Policy
  • Cookie Policy
Contact us
  • T:+44 (0) 208 168 1668
  • US Toll Free:+1 628 201 0911
  • [javascript protected email address]
  • The London Bioscience Innovation Centre (LBIC)
    2 Royal College Street
    London NW1 0NH

©2023 PharmaMedic. All Rights Reserved | Company Registration Number: 07364364 | VAT: 135986768

Powered by FL1 Digital